In contrast, and based on the importance of CD8+ T cells for protection against leishmaniasis and a range of other intracellular pathogens, we have sought to develop a novel therapeutic vaccine for VL / PKDL, biased towards the induction of CD8+ T cell responses. This evidence concerns the gene CD8A and leishmaniasis.